Long-acting injectable implant shows promise for HIV treatment and prevention
October 09, 2018 / University of North Carolina at Chapel Hill School
A persistent challenge in HIV/AIDS treatment and prevention is medication adherence – getting patients to take their medication as required to get the best results. Currently, a once-daily pill to prevent HIV infection is available. However, adherence to a once-daily regimen can be difficult for some people. Researchers from the UNC School of Medicine and the Centers for Disease Control and Prevention published a study today in Nature Communications that reports a potentially promising remedy for this problem. The researchers developed an ultra-long-acting, injectable, and removable formulation of an antiretroviral medication called dolutegravir, and they tested the formulation's effectiveness in animal models.